Aphios Presents At Anti-Infectives Infectious Diseases Summit
November 07, 2011
Woburn, MA— Dr. Trevor P. Castor, President and CEO, Aphios® Corporation, will present Aphios' Anti-Infectives Program at the Global Technology Community's 8th Annual Anti-Infectives Conference at the Infectious Diseases World Summit, held at the Omni Parker House, Boston, MA on November 7th-8th, 2011.

A core component of Aphios' Anti-Infectives program is SFS-CFI virus inactivation technology for enveloped viruses such as HIV and non-enveloped viruses such as B19 and EMC to improve the safety of human plasma, plasma products, monoclonal antibodies and other recombinant proteins.

Aphios also utilizes its unique library of marine organisms, patented SFS-CXF technology, and viral and microbial targets to discover and develop novel anti-infectives.

"To date, our research program has generated several novel anti-HIV and anti-influenza 'hits,' as well as MRSA and marine anti-plaque leads," says Dr. Castor. "Other HIV antiviral therapeutics being researched include nanoHYP™, which is a nanoformulation of a photo-sensitive molecule, and a chemiluminescent substrate that acts like a molecular flashlight to activate photo-sensitive molecules to kill HIV and other pathogens inside the body as well as ex vivo in red blood cells; and Albaspheres™, an oral nanoformulation of betulinic acid that works as an HIV maturation inhibitor."

Aphios has developed and patented an HIV/AIDS therapeutic vaccine based on inactivated HIV using SFS-CFI technology, and a vaccine adjuvant technology consisting of polymer nanospheres using its proprietary and patented SuperFluids™ PNS technology for anthrax rPA and other subunit vaccines.

Aphios' lead anti-infective therapeutic product in development is APH-0812, a combination therapy consisting of Protein Kinase C (PKC) modulators and Histone Deacetylase (HDAC) inhibitors, designed to reactivate latent HIV reservoirs so that HIV can be eliminated by antiviral therapy and eradicated from the body.

"Our researchers have found that the PKC modulator down regulates the expression of the HIV-1 receptors CD4 and CXCR4 and thus is a candidate for treating HIV-1 latency," explains Dr. Castor. "We have also discovered that the PKC modulator synergizes with HDAC inhibitors to antagonize HIV-1 latency." Aphios hopes to announce a human clinical trial of APH-0812 in Spain in the first or second quarter of 2012.

Aphios® Corporation is a green biotechnology company developing enabling technology platforms for improved drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Based on these platforms, Aphios is developing enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and central nervous system disorders, such as Alzheimer 's disease.